Data_Sheet_1_Vaccination with SARS-CoV-2 inactivated vaccines reduced the risk of anxiety and depression in a population majored by health care workers during the recent omicron variant outbreak.doc

BackgroundThe mental health status of the population majored by health care workers in China during the omicron variant outbreak remains unknown. Furthermore, the effect of COVID-19-inactivated vaccines on mental health is yet to be investigated.MethodsA cross-sectional, online survey study was conducted from 12–20 April, 2022. The prevalence of symptoms of depression and anxiety were evaluated using the Hospital Anxiety and Depression Scale.ResultsResponses from a total of 1,387 participants were analyzed, 39.7% of which reported symptoms of mental health illness. The incidence of anxiety (30.4% vs. 48.4%, p ConclusionOur findings increase the awareness of the high incidence of mental health illness symptoms during the omicron variant outbreak despite previous experiences with the COVID-19 pandemic, and vaccination is suggested to reduce the risk of anxiety and depression.</p

Additional file 1 of The burden and predictors of 30-day unplanned readmission in patients with acute liver failure: a national representative database study

Supplementary Material

Intraoperative blood loss, intubation and ICU staying time in the artificial liver support system (ALSS)-liver transplantation (LT) group and LT group.

<p>Intraoperative blood loss, intubation and ICU staying time in the artificial liver support system (ALSS)-liver transplantation (LT) group and LT group.</p

Changes of key laboratory parameters pre- and post-artificial liver support system (ALSS) treatment in different subgroups.

<p>Removal rate was calculated as: (pre-treatment concentration—post-treatment concentration)/pre-treatment concentration.</p><p>Abbreviations: PE, plasma exchange; TB, total bilirubin; Cr, creatinine; PT, prothrombin time.</p

The baseline patient characteristics.

<p>Abbreviations: ALSS, artificial liver support system; LT, liver transplantation; TB, total bilirubin; MELD, model for End-Stage Liver Disease; HBV, hepatitis B virus.</p

Liver function and model for End-Stage Liver Disease (MELD) score before artificial liver support system (ALSS) and before liver transplantation (LT).

<p>Abbreviations: TB, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBA, total bile acid;</p

Data_Sheet_1_Prognosis prediction performs better in patients with non-cirrhosis hepatitis B virus-related acute-on-chronic liver failure than those with cirrhosis.docx

BackgroundThe accurate prediction of the outcome of hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is impeded by population heterogeneity. The study aimed to assess the impact of underlying cirrhosis on the performance of clinical prediction models (CPMs).MethodsUsing data from two multicenter, prospective cohorts of patients with HBV-ACLF, the discrimination, calibration, and clinical benefit were assessed for CPMs predicting 28-day and 90-day outcomes in patients with cirrhosis and those without, respectively.ResultsA total of 919 patients with HBV-ACLF were identified by Chinese Group on the Study of Severe Hepatitis B (COSSH) criteria, including 675 with cirrhosis and 244 without. COSSH-ACLF IIs, COSSH-ACLFs, Chronic Liver Failure-Consortium Acute-on-Chronic Liver Failure score (CLIF-C ACLFs), Tongji Prognostic Predictor Model score (TPPMs), Model for End-Stage Liver Disease score (MELDs), and MELD-Sodium score (MELD-Nas) were all strong predictors of short-term mortality in patients with HBV-ACLF. In contrast to a high model discriminative capacity in ACLF without cirrhosis, each prognostic model represents a marked decline of C-index, net reclassification index (NRI), and integrated discrimination improvement (IDI) in predicting either 28-day or 90-day prognosis of patients with cirrhosis. The hazard analysis identified largely overlapping risk factors of poor outcomes in both subgroups, while serum bilirubin was specifically associated with short-term mortality in patients with cirrhosis and blood urea nitrogen in patients without cirrhosis. A subgroup analysis in patients with cirrhosis showed a decline of discrimination of CPMS in those with ascites or infections compared to that in those without.ConclusionPredicting the short-term outcome of HBV-ACLF by CPMs is optimal in patients without cirrhosis but limited in those with cirrhosis, at least partially due to the complicated ascites or infections.</p